• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从患者角度看新型口服抗凝药物(NOACs)的安全性概况:基于网络的队列事件监测研究。

Safety profile of non-vitamin K oral anticoagulants (NOACs) from a patient perspective: a web-based cohort event monitoring study.

机构信息

a Netherlands Pharmacovigilance Centre Lareb , 's-Hertogenbosch , The Netherlands.

b Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, - Epidemiology & -Economics, University of Groningen , Groningen , The Netherlands.

出版信息

Expert Opin Drug Saf. 2019 Sep;18(9):869-874. doi: 10.1080/14740338.2019.1645120. Epub 2019 Jul 22.

DOI:10.1080/14740338.2019.1645120
PMID:31311346
Abstract

: Non-vitamin K oral anticoagulants (NOACs) are a relatively new group of anticoagulants. Characteristics of adverse drug reactions (ADRs) as experienced by patients in everyday use have not yet been fully clarified. The aim was to gain insight into the safety profile of NOACs from a patient's perspective. : This was a prospective, observational web-based cohort event monitoring study among first-time users of NOACs. Patients were recruited between July 2012 and April 2017. They were invited to complete four web-based questionnaires 2 weeks, 5 weeks, 3 months and 6 months after starting treatment. Information was collected about patient characteristics, drug use, and characteristics of ADRs. : 1748 NOAC users were included. 661 (38%) experienced at least one ADR. The reported ADRs were comparable with the information described in the Summary of Product Characteristics and generally occurred within 1 week after the start. In 59% of ADRs the patients recovered. These ADRs had no impact on the use and dosage of the NOAC in 68%. In total, 9% of the patients discontinued the NOAC because of ADRs. : Overall NOACs were well tolerated by the participants. Most reported ADRs occurred within 1 week after the start. Patients recovered from most ADRs without changes to the use of the NOAC.

摘要

: 非维生素 K 口服抗凝剂(NOACs)是一组相对较新的抗凝剂。患者在日常使用中经历的不良反应(ADRs)特征尚未完全阐明。目的是从患者的角度了解 NOACs 的安全性概况。 : 这是一项针对首次使用 NOACs 的患者的前瞻性、观察性、基于网络的队列事件监测研究。患者于 2012 年 7 月至 2017 年 4 月期间招募。他们被邀请在开始治疗后 2 周、5 周、3 个月和 6 个月时完成四次基于网络的问卷。收集了有关患者特征、药物使用以及 ADR 特征的信息。 : 共纳入 1748 名 NOAC 用户。661 名(38%)至少经历了一次 ADR。报告的 ADR 与产品特性摘要中描述的信息相似,通常发生在开始后 1 周内。59%的 ADR 患者康复。这些 ADR 对 68%的 NOAC 的使用和剂量没有影响。共有 9%的患者因 ADR 而停止使用 NOAC。 : 总体而言,NOACs 被参与者耐受良好。大多数报告的 ADR 发生在开始后 1 周内。大多数 ADR 患者无需更改 NOAC 的使用即可康复。

相似文献

1
Safety profile of non-vitamin K oral anticoagulants (NOACs) from a patient perspective: a web-based cohort event monitoring study.从患者角度看新型口服抗凝药物(NOACs)的安全性概况:基于网络的队列事件监测研究。
Expert Opin Drug Saf. 2019 Sep;18(9):869-874. doi: 10.1080/14740338.2019.1645120. Epub 2019 Jul 22.
2
Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study.葡萄牙口服抗凝剂疑似药物不良反应报告:一项药物警戒研究。
Expert Opin Drug Saf. 2018 Apr;17(4):339-345. doi: 10.1080/14740338.2018.1439474. Epub 2018 Feb 20.
3
Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information.对普瑞巴林的强化监测:一项基于网络的前瞻性荷兰队列研究结果,该研究利用患者作为信息来源。
Drug Saf. 2011 Mar 1;34(3):221-31. doi: 10.2165/11585030-000000000-00000.
4
Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.急性缺血性脑卒中患者的再通治疗:新型口服抗凝剂治疗对出血并发症和结局的影响。
Circulation. 2015 Sep 29;132(13):1261-9. doi: 10.1161/CIRCULATIONAHA.115.015484. Epub 2015 Jul 31.
5
[Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants].[药物不良反应报告不足,这一问题也涉及到需额外监测的药物。来自关于新型口服抗凝剂的单中心经验的初步数据]
G Ital Cardiol (Rome). 2018 Jan;19(1):54-61. doi: 10.1714/2852.28779.
6
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.新型口服抗凝药(NOACs)的处方量已超过华法林:探究医生如何选择抗凝治疗药物。
Eur J Clin Pharmacol. 2018 Mar;74(3):323-330. doi: 10.1007/s00228-017-2374-4. Epub 2017 Nov 17.
7
Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands.荷兰抗血栓药物的使用趋势以及对非维生素K口服抗凝剂的依从性
Int J Clin Pharm. 2015 Dec;37(6):1128-35. doi: 10.1007/s11096-015-0174-4. Epub 2015 Aug 5.
8
New Anticoagulant Agents: Incidence of Adverse Drug Reactions and New Signals Thereof.新型抗凝药物:不良反应的发生情况及其新信号。
Semin Thromb Hemost. 2019 Mar;45(2):196-204. doi: 10.1055/s-0038-1657783. Epub 2018 Jun 4.
9
Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.非维生素K拮抗剂口服抗凝药在心房颤动患者中的应用:来自专科心房颤动诊所的见解
Int J Clin Pract. 2015 Nov;69(11):1341-8. doi: 10.1111/ijcp.12712. Epub 2015 Aug 3.
10
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.在 1 年随访期间,接受稳定维生素 K 拮抗剂治疗或换用非维生素 K 拮抗剂口服抗凝剂的心房颤动患者的生活质量和患者满意度:AF 登记处的 PREFER 子研究。
Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21.

引用本文的文献

1
Medication Adherence to Direct Oral Anticoagulants: Extent and Impact of Side Effects.直接口服抗凝剂的药物依从性:副作用的程度及影响
Patient Prefer Adherence. 2024 Aug 23;18:1779-1788. doi: 10.2147/PPA.S463164. eCollection 2024.
2
Development of a Framework Structuring Themes in the Course of Adverse Drug Reactions from a Patient's Perspective.从患者角度构建药物不良反应主题框架的研究进展。
Drug Saf. 2023 Oct;46(10):1039-1047. doi: 10.1007/s40264-023-01343-y. Epub 2023 Aug 31.